Merck (BUE:MRK) Additional Paid-In Capital : ARS16,067,749 Mil(As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Merck Additional Paid-In Capital?

Merck's quarterly additional paid-in capital increased from Jun. 2023 (ARS10,612,560 Mil) to Sep. 2023 (ARS15,523,083 Mil) and increased from Sep. 2023 (ARS15,523,083 Mil) to Dec. 2023 (ARS16,067,749 Mil).

Merck's annual additional paid-in capital increased from Dec. 2021 (ARS4,467,596 Mil) to Dec. 2022 (ARS7,440,139 Mil) and increased from Dec. 2022 (ARS7,440,139 Mil) to Dec. 2023 (ARS16,067,749 Mil).

Merck Additional Paid-In Capital Historical Data

The historical data trend for Merck's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Additional Paid-In Capital Chart

Merck Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

2,370,620.97

3,221,671.32

4,467,595.53

7,440,139.14

16,067,749.01

Merck Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															7,440,139.14	8,784,456.05	10,612,559.92	15,523,082.53	16,067,749.01

Merck Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Merck Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Merck's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck (BUE:MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BUE:MRK) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MRK:USA MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany MRK:Chile MRCK34:Brazil MRK:Austria

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.